2-Acetamido-6-aminopyrazine | 74273-74-8

• 分子结构分类: 有机化合物 - 有机氮化合物
• 英文名称: 2-Acetamido-6-aminopyrazine
• 英文别名: N-(6-aminopyrazin-2-yl)acetamide
• CAS: 74273-74-8
• 化学式: C₆H₈N₄O
• 分子量: 152.156
• InChiKey: NJJLCRDAOQFMDD-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -0.2
• 重原子数：
  11
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.17
• 拓扑面积：
  80.9
• 氢给体数：
  2
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  2-Acetamido-6-aminopyrazine 在 N-溴代丁二酰亚胺(NBS) 作用下， 以 乙腈 为溶剂， 反应 4.0h， 以76%的产率得到N-(6-amino-3,5-dibromopyrazin-2-yl)acetamide
  参考文献：
  名称：

  WO2020073011A5

  摘要：

  公开号：

  WO2020073011A5
• 作为产物：
  描述：

  2-Acetamido-6-azidopyrazine 在 palladium on activated charcoal ammonium hydroxide 、 氢气 作用下， 以 乙醇 为溶剂， 反应 2.0h， 以78%的产率得到2-Acetamido-6-aminopyrazine
  参考文献：
  名称：

  Shaw, John T.; Brotherton, Christine E.; Moon, Robert W., Journal of Heterocyclic Chemistry, 1980, vol. 17, p. 11 - 16

  摘要：

  DOI：

文献信息

• SHAW J. T.; BROTHERTON C. E.; MOON R. W.; WINLAND M. D.; ANDERSON M. D.; +, J. HETEROCYCL. CHEM., 1980, 17, NO 1, 11-16
  作者：SHAW J. T.、 BROTHERTON C. E.、 MOON R. W.、 WINLAND M. D.、 ANDERSON M. D.、 +

  DOI：——

  日期：——
• COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH APJ RECEPTOR ACTIVITY
  申请人：Annapurna Bio Inc.

  公开号：EP3860998A1

  公开（公告）日：2021-08-11
• [EN] COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH APJ RECEPTOR ACTIVITY<br/>[FR] COMPOSÉS ET COMPOSITIONS DESTINÉS AU TRAITEMENT D'ÉTATS PATHOLOGIQUES ASSOCIÉS À UNE ACTIVITÉ DU RÉCEPTEUR DE L'APJ
  申请人：ANNAPURNA BIO INC

  公开号：WO2020073011A1

  公开（公告）日：2020-04-09

  This disclosure features chemical entities (e.g., a compound or a pharmaceutically acceptable salt and/or hydrate and/or prodrug of the compound) that modulate (e.g., agonize) the apelin receptor (also referred to herein as the APJ receptor; gene symbol APLNR). This disclosure also features compositions containing the same as well as other methods of using and making the same. The chemical entities are useful, e.g., for treating a subject (e.g., a human) having a disease, disorder, or condition in which a decrease in APJ receptor activity (e.g., repressed or impaired APJ receptor signaling; e.g., repressed or impaired apelin-APJ receptor signaling) or downregulation of endogenous apelin contributes to the pathology and/or symptoms and/or progression of the disease, disorder, or condition. Non-limiting examples of such diseases, disorders, or conditions include: (i) cardiovascular disease; (ii) metabolic disorders; (iii) diseases, disorders, and conditions associated with vascular pathology; and (iv) organ failure; (v) diseases, disorders, and conditions associated with infections (e.g., microbial infections); and (vi) diseases, disorders, or conditions that are sequela or comorbid with any of the foregoing or any disclosed herein. More particular non-limiting examples of such diseases, disorders, or conditions include pulmonary hypertension (e.g., PAH); heart failure; type II diabetes; renal failure; sepsis; and systemic hypertension.
• WO2020073011A5
  申请人：——

  公开号：WO2020073011A5

  公开（公告）日：2022-10-12
• Shaw, John T.; Brotherton, Christine E.; Moon, Robert W., Journal of Heterocyclic Chemistry, 1980, vol. 17, p. 11 - 16
  作者：Shaw, John T.、Brotherton, Christine E.、Moon, Robert W.、Winland, Mark D.、Anderson, Mark D.、Kyler, Keith S.

  DOI：——

  日期：——